The emerging role of nanobiomaterials in the early detection and treatment of Alzheimer’s disease

Abstract

The neurodegenerative condition known as Alzheimer’s disease (AD) is defined chiefly by intraneuronal tangles, large-scale neuronal death, and dementia. Although much progress has been made in Alzheimer’s research, early diagnosis of the disease and effective treatment are difficult; conventional diagnostic tests fail to detect the pathology until there is significant neurodegeneration, and many treatments do not penetrate the blood-brain barrier and have poor target specificity. Nanotechnology has the ability to completely transform neurodegenerative disease diagnosis and treatment. Sensitive molecule detection, efficient drug targeting, and integration are possible through nanotechnology-based diagnostic tools, drug delivery mechanisms, and medicines. A great deal has been achieved in the last decade with respect to this, and favorable outcomes in the therapy of AD have been witnessed. The objective of this review is to critically assess the novel potential of nanobiomaterials for early detection and treatment of AD, highlighting their contributions to sensitive biomarker detection, targeted drug delivery, multimodal imaging, and the challenges of clinical translation.

Keywords

Alzheimer’s disease / nanotechnology / nanotherapeutics / theragnostic / procedures

References

[1] Ayinla MT, Asuku AO, Bayo-Olugbami A, Ayeni OA, Abiola AA, Owoyele BV. Melatonin and Vitamin C modulate cholinergic neurotransmission and oxidative stress in scopolamine-induced rat model of dementia. J Afr Assoc Physiol Sci. 2020; 8:50-8.

[2] Asuku AO, Ayinla MT, Gbonjubola OO, Babatunde SS, Olajide TS, Oyerinde TO. Neurocognitive Aspects of Dementia. Nutr Neurosci. 2024109-30.

[3] Asuku AO, Ajagun EJ, Oyinlola Ogungbangbe G. editors.Non-Pharmacological Interventions for Dementia: A Comprehensive Approach1st edBoca Raton: CRC Press; 2025

[4] Knopman DS, Amieva H, Petersen RC, Chételat G, Holtzman DM, Hyman BT, et al.Alzheimer disease. Nat Rev Dis Primers. 2021; 7:33.

[5] Long JM, Holtzman DM. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell. 2019; 179:312-39.

[6] Asuku AO, Adeyemo MB, Adeyemo RO, Agoro SA, Odugbesan OA, Ayoola SA. Applications of stem cell therapy in neurodegenerative diseases. Eur J Biotechnol Biosci. 2022; 10:17-24.

[7] Khan S, Barve KH, Kumar MS. Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease. Curr Neuropharmacol. 2020; 18:1106-25.

[8] Tackenberg C, Kulic L, Nitsch RM. Familial Alzheimer’s disease mutations at position 22 of the amyloid β-peptide sequence differentially affect synaptic loss, tau phosphorylation and neuronal cell death in an ex vivo system. PLoS ONE. 2020; 15:e0239584.

[9] Wang H, Kulas JA, Wang C, Holtzman DM, Ferris HA, Hansen SB. Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol. Proc Natl Acad Sci. 2021; 118:e118.

[10] Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules. 2020; 25:5789.

[11] Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, Ganguli M, Gloss D, et al.Practice guideline update summary: Mild cognitive impairment [RETIRED]. Neurology. 2018; 90:126-35.

[12] Tzioras M, Davies C, Newman A, Jackson R, Spires-Jones T. Invited Review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer's disease. Neuropathol Appl Neurobiol. 2018; 45:327-46.

[13] Sinyor B, Mineo J, Ochner C. Alzheimer’s Disease, Inflammation, and the Role of Antioxidants. J Alzheimers Dis Rep. 2020; 4:175-83.

[14] Lin X, Kapoor A, Gu Y, Chow MJ, Peng J, Zhao K, et al.Contributions of DNA Damage to Alzheimer’s Disease. Int J Mol Sci. 2020; 21:1666.

[15] Lloret MA, Cervera-Ferri A, Nepomuceno M, Monllor P, Esteve D, Lloret A. Is Sleep Disruption a Cause or Consequence of Alzheimer’s Disease? Reviewing Its Possible Role as a Biomarker. Int J Mol Sci. 2020; 21:1168.

[16] Huat TJ, Camats-Perna J, Newcombe EA, Valmas N, Kitazawa M, Medeiros R. Metal Toxicity Links to Alzheimer’s Disease and Neuroinflammation. J Mol Biol. 2019; 431:1843-68.

[17] Alves GS, Oertel Knöchel V, Knöchel C, Carvalho AF, Pantel J, Engelhardt E, et al.Integrating Retrogenesis Theory to Alzheimer’s Disease Pathology: Insight from DTI-TBSS Investigation of the White Matter Microstructural Integrity. BioMed Res Int. 2015; 2015:291658.

[18] Luczynski P, Laule C, Hsiung GR, Moore GRW, Tremlett H. Coexistence of Multiple Sclerosis and Alzheimer's disease: A review. Mult Scler Relat Disord. 2019; 27:232-8.

[19] Alahmari A. Blood-Brain Barrier Overview: Structural and Functional Correlation. Neural Plast. 2021; 2021:6564585.

[20] Mulvihill JJ, Cunnane EM, Ross AM, Duskey JT, Tosi G, Grabrucker AM. Drug Delivery Across The Blood-Brain Barrier: Recent Advances in The Use of Nanocarriers. Nanomedicine. 2020; 15:205-14.

[21] Asuku AO, Ayinla MT, Sesan Abiodun Aransiola, Adeyemo RO. Chitosan-Based Nanoparticles to Bypass the Blood-Brain Barrier for the Treatment of Neurological Diseases: A Review. Pac J Med Sci. 2024; 25:45-65.

[22] Nayab DE, Din FU, Ali H, Kausar WA, Urooj S, Zafar M, et al.Nano biomaterials based strategies for enhanced brain targeting in the treatment of neurodegenerative diseases: an up-to-date perspective. J Nanobiotechnology. 2023; 21:477.

[23] Martín-Rapun R, De Matteis L, Ambrosone A, Garcia-Embid S, Gutierrez L, de la Fuente JM. Targeted Nanoparticles for the Treatment of Alzheimer’s Disease. Curr Pharm Des. 2017; 23:1927-52.

[24] Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res. 2016; 33:2373-87.

[25] FDA Approves Treatment for Adults with Alzheimer’s Disease [Internet].U.S. Food and Drug Administration; [cited 2024 Jul 2]. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease

[26] Kaur H, Phanden RK, Singh RK, Sikarwar BS. In: Discovery, Disruption, and Future Implications of Nanomaterials (2 Volumes). Hershey: IGI Global; 2024.

[27] Li Y, Liu R, Ji W, Li Y, Liu L, Zhang X. Delivery systems for theranostics in neurodegenerative diseases. Nano Res. 2018; 11:5535-55.

[28] Altinoglu G, Adali T. Alzheimer’s Disease Targeted Nano-Based Drug Delivery Systems. Curr Drug Targets. 2020; 21:628-46.

[29] Villalva MD, Agarwal V, Ulanova M, Sachdev PS, Braidy N. Quantum Dots as A Theranostic Approach in Alzheimer’s Disease: A Systematic Review. Nanomedicine. 2021; 16:1595-611.

[30] Utkin YN. Brain and Quantum Dots: Benefits of Nanotechnology for Healthy and Diseased Brain. Cent Nerv Syst Agents Med Chem. 2018; 18:193-205.

[31] Wu T, Zhang T, Chen Y, Tang M. Research advances on potential neurotoxicity of quantum dots. J Appl Toxicol. 2015; 36:345-51.

[32] Dong J, Tao L, Abourehab MAS, Hussain Z. Design and development of novel hyaluronate-modified nanoparticles for combo-delivery of curcumin and alendronate: fabrication, characterization, and cellular and molecular evidences of enhanced bone regeneration. Int J Biol Macromol. 2018; 116:1268-81.

[33] Zhang W, Sigdel G, Mintz KJ, Seven ES, Zhou Y, Wang C, et al.Carbon Dots: A Future Blood-Brain Barrier Penetrating Nanomedicine and Drug Nanocarrier. Int J Nanomed. 2021; 16:5003-16.

[34] Waris A, Din M, Ali A, Ali M, Afridi S, Baset A, et al.A comprehensive review of green synthesis of copper oxide nanoparticles and their diverse biomedical applications. Inorg Chem Commun. 2021; 123:108369.

[35] Shan D, Ma C, Yang J. Enabling biodegradable functional biomaterials for the management of neurological disorders. Adv Drug Deliv Rev. 2019; 148:219-38.

[36] Muheem A, Jahangir MA, Jaiswal CP, Jafar M, Ahmad MZ, Ahmad J, et al.Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders. Curr Drug Metab. 2021; 22:263-79.

[37] Waris A, Ali A, Khan AU, Asim M, Zamel D, Fatima K, et al.Applications of Various Types of Nanomaterials for the Treatment of Neurological Disorders. Nanomaterials. 2022; 12:2140.

[38] Leiro V, Duque Santos S, Lopes CDF, Paula Pêgo A. Dendrimers as Powerful Building Blocks in Central Nervous System Disease: Headed for Successful Nanomedicine. Adv Funct Mater. 2017; 28:e28.

[39] Mignani S, Rodrigues J, Tomas H, Roy R, Shi X, Majoral JP. Bench-to-bedside translation of dendrimers: Reality or utopia? A concise analysis. Adv Drug Deliv Rev. 2018; 136–137:73-81.

[40] Xiang C, Zhang Y, Guo W, Liang XJ. Biomimetic carbon nanotubes for neurological disease therapeutics as inherent medication. Acta Pharm Sin B. 2020; 10:239-48.

[41] Komane PP, Choonara YE, du Toit LC, Kumar P, Kondiah PPD, Modi G, et al.Diagnosis and Treatment of Neurological and Ischemic Disorders Employing Carbon Nanotube Technology. J Nanomater. 2016; 2016:1-19.

[42] Hussain Z, Pandey M, Thu HE, Kaur T, Jia GW, Ying PC, et al.Hyaluronic acid functionalization improves dermal targeting of polymeric nanoparticles for management of burn wounds: In vitro, ex vivo and in vivo evaluations. Biomed Pharmacother. 2022; 150:112992.

[43] Fontes MAP, Vaz GC, Cardoso TZD, de Oliveira MF, Campagnole-Santos MJ, Dos Santos RAS, et al.GABA-containing liposomes: neuroscience applications and translational perspectives for targeting neurological diseases. Nanomed: Nanotechnol Biol Med. 2018; 14:781-8.

[44] Patel MM, Patel BM. Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain. CNS Drugs. 2017; 31:109-33.

[45] Furtado D, Björnmalm M, Ayton S, Bush AI, Kempe K, Caruso F. Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. Adv Mater. 2018; 30:e1801362.

[46] Yin T, Yang L, Liu Y, Zhou X, Sun J, Liu J. Sialic acid (SA)-modified selenium nanoparticles coated with a high blood-brain barrier permeability peptide-B6 peptide for potential use in Alzheimer’s disease. Acta Biomater. 2015; 25:172-83.

[47] Chen C, Long L, Zhang F, Chen Q, Chen C, Yu X, et al.Antifungal activity, main active components and mechanism of Curcuma longa extract against Fusarium graminearum. PLOS ONE. 2018; 13:e0194284.

[48] Shabbir U, Rubab M, Tyagi A, Oh DH. Curcumin and Its Derivatives as Theranostic Agents in Alzheimer’s Disease: The Implication of Nanotechnology. Int J Mol Sci. 2020; 22:196.

[49] Cheng KK, Yeung CF, Ho SW, Chow SF, Chow AH, Baum L. Highly Stabilized Curcumin Nanoparticles Tested in an In Vitro Blood-Brain Barrier Model and in Alzheimer’s Disease Tg2576 Mice. AAPS J. 2012; 15:324-36.

[50] Fox LJ, Richardson RM, Briscoe WH. PAMAM dendrimer—cell membrane interactions. Adv Colloid Interface Sci. 2018; 257:1-18.

[51] Song S, Wu J, Cheng Y, Ma L, Liu T, Liu J, et al.Emerging two-dimensional materials-enabled diagnosis and treatments of Alzheimer’s disease: Status and future challenges. Appl Mater Today. 2021; 23:101028.

[52] Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al.NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018; 14:535-62.

[53] Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, et al.The Alzheimer’s Association Appropriate Use Recommendations for Blood Biomarkers in Alzheimer’s Disease. Alzheimers Dement. 2022; 18:e18.

[54] Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Suárez-Calvet M, et al.Diagnostic performance and prediction of clinical progression of plasma phosphor-tau181 in the Alzheimer’s Disease Neuroimaging Initiative. Mol Psychiatry. 2020; 26:429-42.

[55] Lin RR, Xue YY, Li XY, Chen YH, Tao QQ, Wu ZY. Optimal Combinations of AT(N) Biomarkers to Determine Longitudinal Cognition in the Alzheimer’s Disease. Front Aging Neurosci. 2021; 13:718959.

[56] Kumar S JT. Theranostics: A Way of Modern Medical Diagnostics and the Role of Chitosan. J Mol Genet Med. 2014; 09:e09.

[57] Aminolroayaei F, Shahbazi-Gahrouei D, Shahbazi-Gahrouei S, Rasouli N. Recent nanotheranostics applications for cancer therapy and diagnosis: A review. IET Nanobiotechnology. 2021; 15:247-56.

[58] Kumar A, Singh P, Kumar D, Dutt S, Kalia P, Kumar R. Biocompatibility and Safety Assessment of Nanomaterials. Prog Drug Res. 202551-76.

[59] Na Y, Bai J, Zhang N, Geng F, Wang X. Nanomaterials for Alzheimer’s disease: emerging strategies in diagnosis and therapy. J Nanobiotechnology. 2026; 24:e24.